Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 9 of 9 entries
Sorted by: Best Match Show Resources per page
Sphingolipids modulate the epithelial-mesenchymal transition in cancer.

Cell death discovery

Levade T, Andrieu-Abadie N, Micheau O, Legembre P, Ségui B.
PMID: 27551437
Cell Death Discov. 2015 Oct 12;1:15001. doi: 10.1038/cddiscovery.2015.1. eCollection 2015.

No abstract available.

Cite
Levade T, Andrieu-Abadie N, Micheau O, et al. Sphingolipids modulate the epithelial-mesenchymal transition in cancer. Cell Death Discov. 2015;1:15001doi: 10.1038/cddiscovery.2015.1.
Levade, T., Andrieu-Abadie, N., Micheau, O., Legembre, P., & Ségui, B. (2015). Sphingolipids modulate the epithelial-mesenchymal transition in cancer. Cell death discovery, 115001. https://doi.org/10.1038/cddiscovery.2015.1
Levade, T, et al. "Sphingolipids modulate the epithelial-mesenchymal transition in cancer." Cell death discovery vol. 1 (2015): 15001. doi: https://doi.org/10.1038/cddiscovery.2015.1
Levade T, Andrieu-Abadie N, Micheau O, Legembre P, Ségui B. Sphingolipids modulate the epithelial-mesenchymal transition in cancer. Cell Death Discov. 2015 Oct 12;1:15001. doi: 10.1038/cddiscovery.2015.1. eCollection 2015. PMID: 27551437; PMCID: PMC4979435.
Copy Download .nbib Format: NLM
Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses.

Cancers

Dubot P, Astudillo L, Therville N, Sabourdy F, Stirnemann J, Levade T, Andrieu-Abadie N.
PMID: 32085512
Cancers (Basel). 2020 Feb 18;12(2). doi: 10.3390/cancers12020475.

The roles of ceramide and its catabolites, i.e., sphingosine and sphingosine 1-phosphate, in the development of malignancies and the response to anticancer regimens have been extensively described. Moreover, an abundant literature points to the effects of glucosylceramide synthase, the...

Cite
Dubot P, Astudillo L, Therville N, et al. Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses. Cancers (Basel). 2020;12(2)doi: 10.3390/cancers12020475.
Dubot, P., Astudillo, L., Therville, N., Sabourdy, F., Stirnemann, J., Levade, T., & Andrieu-Abadie, N. (2020). Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses. Cancers, 12(2), . https://doi.org/10.3390/cancers12020475
Dubot, Patricia, et al. "Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses." Cancers vol. 12,2 (2020). doi: https://doi.org/10.3390/cancers12020475
Dubot P, Astudillo L, Therville N, Sabourdy F, Stirnemann J, Levade T, Andrieu-Abadie N. Are Glucosylceramide-Related Sphingolipids Involved in the Increased Risk for Cancer in Gaucher Disease Patients? Review and Hypotheses. Cancers (Basel). 2020 Feb 18;12(2). doi: 10.3390/cancers12020475. PMID: 32085512; PMCID: PMC7072201.
Copy Download .nbib Format: NLM
Untargeted lipidomic analysis of primary human epidermal melanocytes acutely and chronically exposed to UV radiation.

Molecular omics

Dalmau N, Andrieu-Abadie N, Tauler R, Bedia C.
PMID: 29748690
Mol Omics. 2018 Jun 12;14(3):170-180. doi: 10.1039/c8mo00060c.

Ultraviolet (UV) radiation present in sunlight has been related to harmful effects on skin such as premature aging and skin cancer. In order to study the effects of UV radiation on skin, many investigations have been carried out at...

Cite
Dalmau N, Andrieu-Abadie N, Tauler R, et al. Untargeted lipidomic analysis of primary human epidermal melanocytes acutely and chronically exposed to UV radiation. Mol Omics. 2018;14(3):170-180doi: 10.1039/c8mo00060c.
Dalmau, N., Andrieu-Abadie, N., Tauler, R., & Bedia, C. (2018). Untargeted lipidomic analysis of primary human epidermal melanocytes acutely and chronically exposed to UV radiation. Molecular omics, 14(3), 170-180. https://doi.org/10.1039/c8mo00060c
Dalmau, Núria, et al. "Untargeted lipidomic analysis of primary human epidermal melanocytes acutely and chronically exposed to UV radiation." Molecular omics vol. 14,3 (2018): 170-180. doi: https://doi.org/10.1039/c8mo00060c
Dalmau N, Andrieu-Abadie N, Tauler R, Bedia C. Untargeted lipidomic analysis of primary human epidermal melanocytes acutely and chronically exposed to UV radiation. Mol Omics. 2018 Jun 12;14(3):170-180. doi: 10.1039/c8mo00060c. PMID: 29748690.
Copy Download .nbib Format: NLM
Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research

Montfort A, Filleron T, Virazels M, Dufau C, Milhès J, Pagès C, Olivier P, Ayyoub M, Mounier M, Lusque A, Brayer S, Delord JP, Andrieu-Abadie N, Levade T, Colacios C, Ségui B, Meyer N.
PMID: 33272982
Clin Cancer Res. 2021 Feb 15;27(4):1037-1047. doi: 10.1158/1078-0432.CCR-20-3449. Epub 2020 Dec 03.

PURPOSE: TNF blockers can be used to manage gastrointestinal inflammatory side effects following nivolumab and/or ipilimumab treatment in patients with advanced melanoma. Our preclinical data showed that anti-TNF could promote the efficacy of immune checkpoint inhibitors.PATIENTS AND METHODS: TICIMEL...

Cite
Montfort A, Filleron T, Virazels M, et al. Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clin Cancer Res. 2020;27(4):1037-1047doi: 10.1158/1078-0432.CCR-20-3449.
Montfort, A., Filleron, T., Virazels, M., Dufau, C., Milhès, J., Pagès, C., Olivier, P., Ayyoub, M., Mounier, M., Lusque, A., Brayer, S., Delord, J. P., Andrieu-Abadie, N., Levade, T., Colacios, C., Ségui, B., & Meyer, N. (2021). Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(4), 1037-1047. https://doi.org/10.1158/1078-0432.CCR-20-3449
Montfort, Anne, et al. "Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,4 (2021): 1037-1047. doi: https://doi.org/10.1158/1078-0432.CCR-20-3449
Montfort A, Filleron T, Virazels M, Dufau C, Milhès J, Pagès C, Olivier P, Ayyoub M, Mounier M, Lusque A, Brayer S, Delord JP, Andrieu-Abadie N, Levade T, Colacios C, Ségui B, Meyer N. Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. Clin Cancer Res. 2021 Feb 15;27(4):1037-1047. doi: 10.1158/1078-0432.CCR-20-3449. Epub 2020 Dec 03. PMID: 33272982.
Copy Download .nbib Format: NLM
Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives.

Cancers

Pellerin L, Carrié L, Dufau C, Nieto L, Ségui B, Levade T, Riond J, Andrieu-Abadie N.
PMID: 33121001
Cancers (Basel). 2020 Oct 27;12(11). doi: 10.3390/cancers12113147.

Metabolic reprogramming contributes to the pathogenesis and heterogeneity of melanoma. It is driven both by oncogenic events and the constraints imposed by a nutrient- and oxygen-scarce microenvironment. Among the most prominent metabolic reprogramming features is an increased rate of...

Cite
Pellerin L, Carrié L, Dufau C, et al. Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives. Cancers (Basel). 2020;12(11)doi: 10.3390/cancers12113147.
Pellerin, L., Carrié, L., Dufau, C., Nieto, L., Ségui, B., Levade, T., Riond, J., & Andrieu-Abadie, N. (2020). Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives. Cancers, 12(11), . https://doi.org/10.3390/cancers12113147
Pellerin, Laurence, et al. "Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives." Cancers vol. 12,11 (2020). doi: https://doi.org/10.3390/cancers12113147
Pellerin L, Carrié L, Dufau C, Nieto L, Ségui B, Levade T, Riond J, Andrieu-Abadie N. Lipid metabolic Reprogramming: Role in Melanoma Progression and Therapeutic Perspectives. Cancers (Basel). 2020 Oct 27;12(11). doi: 10.3390/cancers12113147. PMID: 33121001; PMCID: PMC7692067.
Copy Download .nbib Format: NLM
Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy.

Cancer immunology research

Montfort A, Bertrand F, Rochotte J, Gilhodes J, Filleron T, Milhès J, Dufau C, Imbert C, Riond J, Tosolini M, Clarke CJ, Dufour F, Constantinescu AA, Junior NF, Garcia V, Record M, Cordelier P, Brousset P, Rochaix P, Silvente-Poirot S, Therville N, Andrieu-Abadie N, Levade T, Hannun YA, Benoist H, Meyer N, Micheau O, Colacios C, Ségui B.
PMID: 33727246
Cancer Immunol Res. 2021 May;9(5):568-582. doi: 10.1158/2326-6066.CIR-20-0342. Epub 2021 Mar 16.

Dysregulation of lipid metabolism affects the behavior of cancer cells, but how this happens is not completely understood. Neutral sphingomyelinase 2 (nSMase2), encoded by

Cite
Montfort A, Bertrand F, Rochotte J, et al. Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy. Cancer Immunol Res. 2021;9(5):568-582doi: 10.1158/2326-6066.CIR-20-0342.
Montfort, A., Bertrand, F., Rochotte, J., Gilhodes, J., Filleron, T., Milhès, J., Dufau, C., Imbert, C., Riond, J., Tosolini, M., Clarke, C. J., Dufour, F., Constantinescu, A. A., Junior, N. F., Garcia, V., Record, M., Cordelier, P., Brousset, P., Rochaix, P., Silvente-Poirot, S., Therville, N., Andrieu-Abadie, N., Levade, T., Hannun, Y. A., Benoist, H., Meyer, N., Micheau, O., Colacios, C., & Ségui, B. (2021). Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy. Cancer immunology research, 9(5), 568-582. https://doi.org/10.1158/2326-6066.CIR-20-0342
Montfort, Anne, et al. "Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy." Cancer immunology research vol. 9,5 (2021): 568-582. doi: https://doi.org/10.1158/2326-6066.CIR-20-0342
Montfort A, Bertrand F, Rochotte J, Gilhodes J, Filleron T, Milhès J, Dufau C, Imbert C, Riond J, Tosolini M, Clarke CJ, Dufour F, Constantinescu AA, Junior NF, Garcia V, Record M, Cordelier P, Brousset P, Rochaix P, Silvente-Poirot S, Therville N, Andrieu-Abadie N, Levade T, Hannun YA, Benoist H, Meyer N, Micheau O, Colacios C, Ségui B. Neutral Sphingomyelinase 2 Heightens Anti-Melanoma Immune Responses and Anti-PD-1 Therapy Efficacy. Cancer Immunol Res. 2021 May;9(5):568-582. doi: 10.1158/2326-6066.CIR-20-0342. Epub 2021 Mar 16. PMID: 33727246.
Copy Download .nbib Format: NLM
Targeting TNF alpha as a novel strategy to enhance CD8.

Oncoimmunology

Bertrand F, Rochotte J, Colacios C, Montfort A, Andrieu-Abadie N, Levade T, Benoist H, Ségui B.
PMID: 26942089
Oncoimmunology. 2015 Aug 12;5(1):e1068495. doi: 10.1080/2162402X.2015.1068495. eCollection 2016.

Tumor Necrosis Factor α (TNF) is a pleiotropic cytokine exhibiting a dual activity in oncoimmunology, either acting as a cytotoxic effector produced by leukocytes or behaving as an immunosuppressive molecule. We have just discovered that TNF signaling impairs the...

Cite
Bertrand F, Rochotte J, Colacios C, et al. Targeting TNF alpha as a novel strategy to enhance CD8. Oncoimmunology. 2015;5(1):e1068495doi: 10.1080/2162402X.2015.1068495.
Bertrand, F., Rochotte, J., Colacios, C., Montfort, A., Andrieu-Abadie, N., Levade, T., Benoist, H., & Ségui, B. (2016). Targeting TNF alpha as a novel strategy to enhance CD8. Oncoimmunology, 5(1), e1068495. https://doi.org/10.1080/2162402X.2015.1068495
Bertrand, Florie, et al. "Targeting TNF alpha as a novel strategy to enhance CD8." Oncoimmunology vol. 5,1 (2016): e1068495. doi: https://doi.org/10.1080/2162402X.2015.1068495
Bertrand F, Rochotte J, Colacios C, Montfort A, Andrieu-Abadie N, Levade T, Benoist H, Ségui B. Targeting TNF alpha as a novel strategy to enhance CD8. Oncoimmunology. 2015 Aug 12;5(1):e1068495. doi: 10.1080/2162402X.2015.1068495. eCollection 2016. PMID: 26942089; PMCID: PMC4760276.
Copy Download .nbib Format: NLM
Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma.

Frontiers in pharmacology

Bilal F, Montfort A, Gilhodes J, Garcia V, Riond J, Carpentier S, Filleron T, Colacios C, Levade T, Daher A, Meyer N, Andrieu-Abadie N, Ségui B.
PMID: 31114500
Front Pharmacol. 2019 Apr 30;10:443. doi: 10.3389/fphar.2019.00443. eCollection 2019.

Sphingolipid (SL) metabolism alterations have been frequently reported in cancer including in melanoma, a bad-prognosis skin cancer. In normal cells,

Cite
Bilal F, Montfort A, Gilhodes J, et al. Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma. Front Pharmacol. 2019;10:443doi: 10.3389/fphar.2019.00443.
Bilal, F., Montfort, A., Gilhodes, J., Garcia, V., Riond, J., Carpentier, S., Filleron, T., Colacios, C., Levade, T., Daher, A., Meyer, N., Andrieu-Abadie, N., & Ségui, B. (2019). Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma. Frontiers in pharmacology, 10443. https://doi.org/10.3389/fphar.2019.00443
Bilal, Fatima, et al. "Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma." Frontiers in pharmacology vol. 10 (2019): 443. doi: https://doi.org/10.3389/fphar.2019.00443
Bilal F, Montfort A, Gilhodes J, Garcia V, Riond J, Carpentier S, Filleron T, Colacios C, Levade T, Daher A, Meyer N, Andrieu-Abadie N, Ségui B. Sphingomyelin Synthase 1 (SMS1) Downregulation Is Associated With Sphingolipid Reprogramming and a Worse Prognosis in Melanoma. Front Pharmacol. 2019 Apr 30;10:443. doi: 10.3389/fphar.2019.00443. eCollection 2019. PMID: 31114500; PMCID: PMC6503817.
Copy Download .nbib Format: NLM
Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy.

Frontiers in immunology

Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B.
PMID: 31695705
Front Immunol. 2019 Oct 22;10:2515. doi: 10.3389/fimmu.2019.02515. eCollection 2019.

[This corrects the article DOI: 10.3389/fimmu.2019.01818.].

Cite
Montfort A, Colacios C, Levade T, et al. Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy. Front Immunol. 2019;10:2515doi: 10.3389/fimmu.2019.02515.
Montfort, A., Colacios, C., Levade, T., Andrieu-Abadie, N., Meyer, N., & Ségui, B. (2019). Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy. Frontiers in immunology, 102515. https://doi.org/10.3389/fimmu.2019.02515
Montfort, Anne, et al. "Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy." Frontiers in immunology vol. 10 (2019): 2515. doi: https://doi.org/10.3389/fimmu.2019.02515
Montfort A, Colacios C, Levade T, Andrieu-Abadie N, Meyer N, Ségui B. Corrigendum: The TNF Paradox in Cancer Progression and Immunotherapy. Front Immunol. 2019 Oct 22;10:2515. doi: 10.3389/fimmu.2019.02515. eCollection 2019. PMID: 31695705; PMCID: PMC6817917.
Copy Download .nbib Format: NLM
Showing 1 to 9 of 9 entries